{
    "id": 31790,
    "fullName": "MAP3K1 A122V",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "MAP3K1 A122V does not lie within any known functional domains of the Map3k1 protein (UniProt.org). A122V has been identified in the scientific literature (PMID: 29795445), but has not been biochemically characterized and therefore, its effect on Map3k1 protein function is unknown (PubMed, Dec 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 17004,
                    "pubMedId": 29795445,
                    "title": "MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29795445"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4214,
        "geneSymbol": "MAP3K1",
        "terms": [
            "MAP3K1",
            "MAPKKK1",
            "MEKK",
            "MEKK 1",
            "MEKK1",
            "SRXY6"
        ]
    },
    "variant": "A122V",
    "createDate": "12/12/2019",
    "updateDate": "12/12/2019",
    "referenceTranscriptCoordinates": {
        "id": 185947,
        "transcript": "NM_005921",
        "gDna": "chr5:g.56815938C>T",
        "cDna": "c.365C>T",
        "protein": "p.A122V",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19528,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient-derived xenograft (PDX) model with cutaneous melanoma harboring MAP3K1 A122V demonstrated reduced tumor volume when treated with Mektovi (binimetinib) (PMID: 29795445).",
            "molecularProfile": {
                "id": 34183,
                "profileName": "MAP3K1 A122V"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17004,
                    "pubMedId": 29795445,
                    "title": "MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29795445"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 34183,
            "profileName": "MAP3K1 A122V",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 185947,
            "transcript": "NM_005921",
            "gDna": "chr5:g.56815938C>T",
            "cDna": "c.365C>T",
            "protein": "p.A122V",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}